Creative Medical Technology Holdings Inc (CELZ)

[Babubd]

Loading up and holding for a reason! Fair value is @ Dollar Land!! Love it! Believe me, we will get THERE!!

It's insanely undervalued, a load and hold hold, no-brainer.

Shorts are screwed-up here. Over 1.11 Billion Shorted volume is outstanding. Shorts are gonna be roasted and burnt.
https://marketwirenews.com/stock/celz/short/

KNOW WHAT YOU OWN

Creative Medical Technology Holdings Recruits Founder of Inc 500 Clinical Trials Company Dr. Boris Reznik to Accelerate Development of ImmCelz(R) Through FDA, Thursday, January 21, 2021 - This is gonna be HUGE beyond imagination!!

PHOENIX, Jan. 21, 2021 /PRNewswire/ -- (OTC -- CELZ) Creative Medical Technology Holdings Inc. announced today recruitment of Dr. Boris Reznik to the Company's Scientific Advisory Board.

Dr. Reznik is a veteran of multiple startups and has a strong track record of building companies across a diverse set of technologies-based industries with biomedical sciences being one of his primary focuses.

His company, Biorasi, global CRO ran an excess of 500 clinical trials and obtained numerous FDA approvals. Dr. Reznik led Biorasi to being awarded the INC 500 "Fastest Growing Company" Award and to a successful exit.

Boris Reznik is the Chairman of Venvalo Group, venture value optimization firm. During his career, Dr. Reznik founded and built technology companies into market leaders and successfully dealt with both Fortune 500 and emerging companies as clients and partners. He has been a lead or co-investor in startups and mid-market firms and has participated in M&A transactions ranging from Millions to Billions. Dr. Reznik has a depth of experience in processes and systems -- a unique perspective in the drug and device development world.

"I am proud to be one of the early investors in Creative Medical Technology Holdings. Its executives are one of the most driven, motivated and talented teams that I have had the pleasure of investing in. I am honored to be invited as a partner to accelerate development of ImmCelz(R) to help patients with heart failure, liver failure, diabetes, and stroke, as well as aiding in their ongoing development of other assets in their robust portfolio" Said Dr. Reznik.

"Working with Dr. Reznik will allow us to "fast forward" the development process of ImmCelz(R), as well as other cellular therapies currently in development." Said Dr. Amit Patel, Board Member of the Company and co-founder. "I have previously collaborated with Dr. Reznik on numerous projects and I am excited to witness the unfolding of Dr. Reznik's life mantra of "Creating Value from Potential(TM)"

"Dr. Reznik's involvement in our clinical development plan, as well as his overall corporate and strategic insight will synergize with our existing strengths to significantly enhance shareholder value." Said Timothy Warbington, President and CEO of the Company. "I enjoy working with Dr. Reznik because of his unique multidisciplinary, multidimensional, "systems based" approach to handling complicated problems. We look forward to bringing life-saving therapies to fruition as quickly as possible."

Creative Medical Technology Holdings Announces Patent filing based on Preclinical Data in Model of Heart Attack using ImmCelz(R) Regenerative Immunotherapy - This is a HUGE News!!

Clinical Stage Stem Cell Company Expands its Cellular Therapy Platforms

PHOENIX, Dec. 31, 2020 /PRNewswire/ -- (OTC -- CELZ) Creative Medical Technology Holdings Inc. announced today positive preclinical data using ImmCelz(R) in treatment of a model of heart attack.

Patent application #63/132472, entitled "Treatment of Heart Failure and/or Post Infarct Pathological Remodeling by Ex Vivo Reprogrammed Immune Cells" covers data in which mice with restricted blood flow to the heart had significantly improved survival when treated with ImmCelz(R) as compared to control mice.

"The role of the immune system in numerous aspects of regenerative medicine can not be overstated." Said Dr. Amit Patel, Board Member of the Company and co-inventor of the patent. "The data described today, while preliminary, supports the belief that ImmCelz(R), which is a "regenerative immunotherapy" can be applied across a broad range of conditions."

The ImmCelz(R) product, based on decades of immunological research by Drs Thomas Ichim and Amit Patel, involves extraction of patient immune cells, "training" the immune cells to exhibit regenerative properties by incubation with regenerative cells outside of the body, followed by re-infusion of the patient's own cells. To date the Company has demonstrated that ImmCelz(R) has therapeutic activity in stroke and liver failure.

"It is my honor that the work we initiated more than a decade ago is coming to fruition." Said Thomas Ichim, Ph.D, coinventor of the patent. "Ten years ago, Dr. Patel, myself and a team of colleagues described the potent synergies that occur when various cell types are utilized in combination for treatment of heart failure(1) . ImmCelz(R) is the product of all these years of working and perfecting multi-cellular approaches to regenerative medicine."

"As we round out 2020, we have significantly expanded our Intellectual Property portfolio based on many years of collaborative research and development. Utilizing the ImmCelz(R) technology for the treatment of heart failure is an excellent addition to this robust patent portfolio as it effects millions of patients in the U.S. alone. Patients with end stage heart failure in many cases have no options but heart transplantation, which is extremely limited." Said Timothy Warbington, President and CEO of the Company. "We are excited with the progress that the Company is making in advancing ImmCelz(R), which approaches regenerative medicine from a completely unique perspective. Given that the active cells in ImmCelz(R) are derived from the same patient, we anticipate an accelerated path to FDA Investigational New Drug (IND) clearance."

"We encourage industry colleagues and other interested parties to review our early priority date patent filings to learn more about the ImmCelz(R) technology and how it applies to multiple indications" Mr. Warbington further said.

CELZ Files Patent on Approaching 10 Billion Dollar Liver Disease Market Using "Reprogrammed" Immune Cells - Wow!!

Creative Medical Technology Holdings Announces Reversion of Liver Failure Using ImmCelz(R) Personalized Cellular Immunotherapy in Preclinical Model

PHOENIX, Dec. 29, 2020 /PRNewswire/ -- (OTC-CELZ) Creative Medical Technology Holdings Inc. announced today novel data and patent filing No. 63131261 describing the ability of ImmCelz(R) to reverse liver failure in the carbon tetrachloride preclinical model of hepatocyte necrosis.

These findings are the basis for a patent filing covering various means of generating the ImmCelz(R) product in a hepatoprotective specific manner. The Company has previously reported that ImmCelz(R) is capable of treating animal models of stroke,(1) as well as inducing "immunological tolerance" in a model of autoimmune rheumatoid arthritis.(2)
The work is an extension of previously published findings of Dr. Thomas E. Ichim, in which mesenchymal stem cells were capable of inhibiting progression of liver failure.(3)

"I am proud of the work the team at Creative Medical Technologies is conducting in advancing the concept of immunologically-mediated regeneration," said Dr. Ichim, Co-inventor of the patent. "ImmCelz(R) is an advancement on our previous liver failure work due to the fact that we have shown transfer of regenerative activity from the stem cell to the immune cell. Immune cells possess ability to home to injured tissues faster than stem cells due to their smaller size. Additionally, immune cells possess immunological memory, which we believe may be applied to the concept of regeneration."

"While stem cell therapeutics are recognized as the future of medicine, I believe it is important to realize that many activities of stem cells are mediated by changes to the immune system," said Dr. Amit Patel, Board Member of the Company and Co-Inventor of the Patent Application. "ImmCelz(R) represents a fundamental advancement in regenerative medicine in that instead of administering stem cells in the body to induce immune modulation, we actually optimize the immune modulation in the laboratory before injecting immune cells into the patient."

Being at the forefront in identifying novel regenerative treatment options, the Company possesses numerous issued patents in the area of cellular therapy, including patent no. 10,842,815 covering use of T regulatory cells for spinal disc regeneration, patent no. 9,598,673 covering stem cell therapy for disc regeneration, patent no. 10,792,310 covering regeneration of ovaries using endothelial progenitor cells and mesenchymal stem cells, patent no. 8,372,797 covering use of stem cells for erectile dysfunction, and patent no. 7,569,385 licensed from the University of California covering a novel stem cell type.

"Liver failure represents a significant unmet medical need and I am extremely excited that ImmCelz(R) has the potential to help the numerous patients on the liver transplant waiting list who currently have no other option.

With growing validation and acceptance of such technologies, the company intends to continue to broaden its intellectual property portfolio by compiling research data and filing patents, in order to record early filing dates and increase the likelihood of our receiving patent issue.

We continue to welcome opportunities with collaborators and Key Opinion Leaders as we are dedicated to accelerating the further development of our technology."

About Creative Medical Technology Holdings

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visit www.creativemedicaltechnology.com.